Stock KURA KURA ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Kura Oncology, Inc.

Equities

KURA

US50127T1097

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
20.61 USD -0.39% Intraday chart for Kura Oncology, Inc. -2.65% +43.32%
May. 24 Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001 CI
May. 15 Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kura Oncology to Participate in Jefferies Global Healthcare Conference
AQ
Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001
CI
Transcript : Kura Oncology, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 10:40 AM
Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug
MT
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
AQ
Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML
CI
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
AQ
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology : Corporate Presentation - May 2024
PU
Kura Oncology: Q1 Earnings Snapshot
AQ
Transcript : Kura Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024
Kura Oncology Reports First Quarter 2024 Financial Results
AQ
Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Kura Oncology to Report First Quarter 2024 Financial Results
AQ
Sector Update: Health Care Stocks Advance Premarket Monday
MT
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy
DJ
Kura Oncology Says Potential Leukemia Drug Ziftomenib Gets FDA Breakthrough Therapy Designation; Shares Rise Pre-Bell
MT
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
AQ
Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KURA Stock
  4. News Kura Oncology, Inc.